Rekah Pharmaceutical Industry Ltd. (TLV: REKA)

Market Cap	163.12M
Revenue (ttm)	324.36M
Net Income (ttm)	6.81M
Shares Out	11.41M
EPS (ttm)	0.57
PE Ratio	25.23
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,239
Open	1,475.00
Previous Close	1,481.00
Day's Range	1,400.00 - 1,475.00
52-Week Range	1,167.00 - 1,679.00
Beta	0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 26, 2024

About REKA

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields. Rekah Pharmaceutical Industry Ltd. was founded in 1...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1941
• Employees: 427
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: REKA

Financial Performance

In 2023, REKA's revenue was 321.66 million, an increase of 10.01% compared to the previous year's 292.39 million. Losses were -6.91 million, 238.6% more than in 2022.